inalimarev

Inalimarev is a cancer vaccine made with a recombinant vaccinia viral vector that encodes tumor-associated antigens, specifically carcinoembryonic antigen (CEA) and MUC1 (mucin-1), both of which are overexpressed in various cancers. The vaccine uses a form of vaccinia virus that does not cause disease in humans. Inalimarev is designed to stimulate the immune system to recognize and attack cancer cells expressing these antigens. It has been studied primarily as part of the Panvac-VF regimen, often combined with another component called falimarev, for use against several solid tumors including colorectal cancer, prostate cancer, pancreatic cancer, and non-small cell lung cancer[1][4][5][6][7].

Brand names

inalimarev

Other names

Panvac-VF (as part of the combination falimarev/inalimarev)